Annotations

Balloon dilatation in congenital heart disease

The relief of stenoses in the cardiovascular system without operation has been made possible by the development of balloon catheters that are small enough to enter peripheral vessels yet strong enough not to deform or rupture when inflated to high pressures. The technique was first used for peripheral vascular stenoses and was later adapted for coronary artery stenoses. Dilatation of congenital cardiac lesions became possible with larger balloons after successful relief of congenital valvular and vascular stenoses had been shown experimentally.1 2

In many cases of congenital aortic stenosis, and in most cases of stenosis of the pulmonary valve, the valve is thick but pliable and obstruction results from fusion of the valve cusp. Dilatation probably splits the valve commissures in the same way as surgical valvotomy, although tearing of the leaflets has been reported.3 Dilatation of arterial lesions, on the other hand, is achieved by splitting the intima and part of the media, leaving the adventitia intact.1 2 The lesions heal by fibrosis, and in the short term restenosis is uncommon.

Technique

The technique of balloon dilatation is similar for all lesions. Assessment of the drop in pressure across the stenosis is followed by angiography to identify the site of obstruction and allow the correct size of balloon to be selected. An end hole catheter is positioned across the stenosis and an exchange guide wire passed through it. The catheter is withdrawn and the deflated balloon catheter passed over the guide wire to straddle the stenosis. As the balloon is inflated with dilute contrast medium the correct positioning of the balloon is indicated by ‘waisting’ at the site of the stenosis. When the pressure rises the waisting disappears as the stenosis is relieved. After dilatation haemodynamic and angiographic assessments are repeated to confirm the success of the procedure.

Indications

In the fairly short period since it was introduced balloon valvuloplasty has become the safe and effective treatment of choice for stenosis of the pulmonary valve after the neonatal period.4 The results achieved are similar to those of surgical valvotomy, with a 60–75% reduction in valve gradient. Balloons 20–30% larger than the diameter of the valve are safe and produce an appreciably greater reduction in valve gradient than smaller balloons.5 Residual obstruction at infundibular level is fairly common but resolves completely within a few months provided that the initial valvuloplasty was successful.3 6 Dysplasia of the pulmonary valve, with thickened, immobile, myxomatous cusps and a small valve annulus, is an uncommon cause of pulmonary stenosis that cannot be cured by valvuloplasty.7 Critical pulmonary stenosis in the neonatal period is still best treated surgically because valvuloplasty is technically difficult and the valves are often dysplastic.

Surgical relief of aortic stenosis in childhood and adolescence is safe and acceptably reduces the valve gradient. Aortic regurgitation is common but rarely important. Aortic valvotomy in childhood is, however, usually palliative, and most patients later require either repeat valvotomy or valve replacement. Technically, aortic valvuloplasty is similar to pulmonary valvuloplasty. The balloon catheter is introduced through the femoral artery. The balloon size is usually 1–2 mm smaller than the aortic valve ring as measured by angiography or echocardiography. The first report of balloon aortic valvuloplasty in 1984 showed that relief of obstruction compared favourably with surgical results and did not produce appreciable valve regurgitation.7 If longer follow up confirms these results valvuloplasty may become the first line treatment for children with aortic stenosis.8

As surgical relief of critical aortic stenosis in the neonate carries a high mortality we have turned increasingly to valvuloplasty as an alternative. It is, however, difficult to introduce large enough catheters into small femoral arteries. Although coronary balloon catheters have been used successfully in small infants, in our experience they are often too small to produce effective dilatation.

In the Western world congenital mitral stenosis is a rare lesion that is unlikely to respond to balloon dilatation because the valve is usually dysplastic. In developing countries, however, rheumatic mitral valve disease is common in childhood and rheumatic stenosis is caused by fusion of the cusp, which can be dilated by balloon angioplasty.8 It requires a trans-
septal approach to the left atrium and is technically difficult, and its role in the long term management of mitral stenosis in children has not been proved.

Both coarctation and recoarctation can be relieved safely and effectively by angioplasty in children over the age of 12 months. Angioplasty is not yet a choice. Neonatal coarctation is not yet a choice. In neonatal period, however, balloon dilatation is the treatment of choice. In recoarctation of the aorta, in pulmonary artery stenosis, and in baffle obstruction after atrial surgery the risks of operation are high and the success rate only moderate. In these cases balloon dilatation is now the treatment of choice. In our experience angioplasty for recoarctation yields encouraging results, although long term follow up is required before we can be certain that it is free of complications. There is a move towards angioplasty for aortic valve stenosis in both children and adults because the results seem to be as good as, and the risks less than, those of surgical valvotomy.

Advantages

Balloon angioplasty for congenital lesions is considerably cheaper than surgery, requires no more than three days in hospital (compared with 10–14 after most operations), and avoids both a surgical scar and postoperative complications. It is, however, technically difficult in some cases and requires high quality angiography. For this reason it remains the tool of cardiologists. There is perhaps a place for balloon angioplasty in developing countries for managing and treating children with rheumatic heart disease.

References

balloon coarctation angioplasty: experience with 27 patients. 

11 Locke JE. Now that we can dilate, should we? *Am J Cardiol* 1984;54:1360.


Stewart Hunter and Christopher Wren
Department of Paediatric Cardiology, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN